Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 24.00p 23.00p 25.00p 24.00p 24.00p 24.00p 235,395 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 0.0 0.0 - 27

Polarean Imaging Share Discussion Threads

Showing 26 to 50 of 50 messages
Chat Pages: 2  1
DateSubjectAuthorDiscuss
16/8/2019
09:54
That will be shifted easily over next 6-8weeks with news coming up, think they have sold a couple of 100k since then, director just bought £80,000 in last placing, he must be very confident, also only 125 million shares in issue I think.
hulk2004
16/8/2019
09:35
They will sell into the news
richardjohn10
16/8/2019
07:55
Massive overhang share price KillerAmphion now holds 18,272,523 ordinary shares in Polarean representing 15.97% of the issued share capital with voting rights. The full TR-1 disclosure is set out below.
hamidahamida
14/8/2019
12:41
They don't want to sell because they know what's on the way!No brainer this stock.CEO buying shed load gives me plenty confidence.
richardjohn10
14/8/2019
07:31
https://www.oilinvestor.co.uk/tech/amphion-innovations-dont-want-to-let-go-off-polarean-imaging-stake/
sja123
12/8/2019
14:07
Covered on V O X again today by an analyst from share price Angel https://www.voxmarkets.co.uk/articles/eco-atlantic-oil-and-gas-and-vadim-alexandre-on-polarean-imaging-8e8569f/ He believes they are undervalued quite some way taking into account their Phase III stage....most drug companies at this stage of development have a much higher valuation....and a much higher chance of failure compared with Polarean...which is pitching a new drug/device tech against a much older and inferior test.... He explains quite well that the Polarean system is unique in that it will be the first time pulmonary consultants will have a clinical test available that actually shows gas exchange between lungs and blood....the present scintigraphy system they are testing against is a snapshot....a picture in time....whereas Polarean tech is, for want of a better comparison, a video....where the whole pulmonary system can be investigated.....and show gas exchange straight into the blood.... Because they can "light up" the polarized xenon....they are also investigating the possibility of this type of test being developed for use in cardiac diagnosis as well.... Worth a listen if you're researching this company....
sja123
09/8/2019
17:19
little surprise at the end there...
global nomad
07/8/2019
08:00
Hi all, I'm researching the company. In the investor symposium Q&A it was stated that under Hatch-Waxman the company should get 5 years of market exclusivity for their Xe129 consumables. Does anyone know what happens after 5 years? Can other people start selling their own Xe129 to be used with the machines? Thanks
mcfly79
02/8/2019
15:21
https://hbr.org/2019/08/4-ways-to-make-evidence-based-practice-the-norm-in-health-care?utm_campaign=hbr&utm_source=twitter&utm_medium=socialAccording to this research in Harvard Business Review it takes on average 17 years to adopt new clinical practices
robertjbeck
01/8/2019
11:18
Razor-razorblade model: Unit sale and recurring drug revenue Polarean is seeking FDA approval as a drug-device combination. If approved, customers using Polarean’s system (‘device’;) will have to use the Company’s 129Xe gas (‘drug’), also exclusively sourced through Polarean. This razor-razorblade model provides the Company with a recurring drug revenue for each patient scanned using the system.
someuwin
01/8/2019
10:09
• Completion of 80-patient Phase 3 trial (data expected in Q4 2019) to drive clinical unit sales • First clinical unit sales expected in H2 2020 • Currently selling units to research institutions • Scope for potential partnerships with big pharma in the near-term Polarean Imaging plc (Polarean) is a revenue-generating company developing a drug-device combination for the magnetic resonance imaging (MRI) market. The Company’s gas polarisation platform provides a non-invasive, radiation-free method to visualise lung structure and function using MRI. The annual burden of pulmonary disease in the US is estimated to be over US$150b. The addition of Polarean’s technology is expected to increase the asset utilisation and profitability of a customer’s MRI system, whilst enabling earlier diagnosis. The Group is currently running two Phase 3 trials for its drug-device platform. The trials are expected to complete enrollment in Q3 2019 and, if successful and approved by the US Food and Drug Administration (FDA), we expect will enable clinical sales of its system, starting by H2 2020. Although yet to receive clinical-approval, Polarean has already sold several polarisers to medical research institutes and remains focused on expanding the installed base of systems through additional sales of research units. Not only is this a source of revenue but it also underlines the academic acceptance of the Group’s technology. We initiate coverage with a BUY rating and a 53p price target.
someuwin
01/8/2019
09:36
Just been reading the recent share price Angel broker note. Have to say this stock looks fantastic.
someuwin
01/8/2019
08:30
You're most welcome GN....nice to see you here....
sja123
01/8/2019
08:29
thanks for the good posts sja, bought in a couple of weeks ago and have added this morning.
global nomad
31/7/2019
13:04
I've taken the plunge! Looking forward to the results!
richardjohn10
31/7/2019
10:39
As you mentioned I'm pretty sure we will pass this test, having used MRI imaging they are vastly outdated not to mention minorly radioactive! This is the main reason it will pass, its safer and more productive. At 29m market cap this is an absolute steal large funds will pile in after this test. Many funds specialise in this field and would never normally invest on aim.
mny1
31/7/2019
10:37
As you mentioned I'm pretty sure we will pass this test, having used MRI imaging they are vastly outdated not to mention minorly radioactive! This is the main reason it will pass, its safer and more productive. At 29m market cap this is an absolute steal large funds will pile in after this test. Many funds specialise in this field and would never normally invest on aim.
mny1
31/7/2019
09:51
I'm hoping the rise will be cumulative Richard....first we are working towards trial results. Perhaps many have yet to catch on that this is no ordinary phase III....many drugs fail to reach their endpoint at this stage but this drug device would seem totally different to me.....I struggle to see how they can fail against the tech they are up against... Again FDA approval doesn't seem a great obstacle here....if the radioactive scintigraphy presently in use is approved, why wouldn't this be? It uses a non radioactive, inert gas to produce beautiful lung images and data... Maybe the Amphion holding worries some at present, who apparently, are a large shareholder in trouble and maybe selling down their holding....but if that is the case, it also provides a good entry price for PIs..... They shrugged off the recent placing with ease and raised at a good price so they have funds now to progress... I've been investing a long time and of course, nothing is nailed on with any company...but every way I look at this looks good to me..... I'm not in it to trade but intend holding for the forseeable.....providing the story doesn't materially change... It's just my opinion....but I like it a lot.....
sja123
31/7/2019
09:17
Without doubt a great bit tech. Do you think if it's nailed on then the results are priced in and the big rise will follow FDA?
richardjohn10
31/7/2019
08:19
mny1...agreed....phase III is non-inferiority....ie. it has to be NO WORSE than is currently available....which is a forty year old tech, radiation based so can't be used too often, with blurry 2D images and no lung function measurements available.. Polarean images are 3D, repeatable because no radiation is involved and show not only lung function and problem areas but the interactions within the pulmonary system ie. gas exchange between lungs and blood..... Polarean are already working on their New Drug Application for the FDA and they are being encouraged to act quickly because there are already drug companies who wish to use this new tech to better test their own new drugs on lung disease and function... They have also said that they are investigating whether this process can be used for cardiac diagnosis as well... There are 35,000 MRI machines around the world and their use has become commonplace in most areas of medicine....except for lung....which, until now, has been notoriously difficult to image and investigate....what hospital radiology department won't want to have this tech available! 25 machines already sold and in use on a trial basis....100 machines operating clinically after approvals together with maintenance, software updates and sale of disposable equipment needed to run them could/would justify a £200m company... Possible ten bags from here on just 100 machines....the prize is huge here if it all works out....I think there is a very good chance it will! All IMO dyor etc
sja123
31/7/2019
07:02
I personally think that if it passes the test ready for fda approval big big funds, bigger than aim will pile in. We are talking something that changes the world globally. Billion pound enterprise.
mny1
31/7/2019
00:22
Maybe one of those shares where you buy a chunk now to give you some exposure and then buy on weakness/good news and build your holding bit by bit.
alloa2003
30/7/2019
15:05
It's a tough call. I get your take on it but once results are out and they file for FDA it could fall back due to timescales? I don't think there's any rush personally. My opinion of course
richardjohn10
30/7/2019
14:58
Now is a great time to buy IMO, CEO bought yesterday now funds are increasing their share. We have just passed by Pols resistance. If you sit on your hands you may miss the boat on this one. We are expecting news to drop any week now on results of the year long tests..
mny1
30/7/2019
07:47
I agree just waiting for right buy in price. Good times ahead:)
richardjohn10
Chat Pages: 2  1
Your Recent History
LSE
POLX
Polarean I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190825 03:23:49